Exploring solid-phase proximity ligation assay for survivin detection in urine.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
02
2022
accepted:
11
06
2022
entrez:
29
6
2022
pubmed:
30
6
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Urine-based biomarkers are a rational and promising approach for the detection of bladder cancer due to the proximity of urine to the location of the tumor site and the non-invasive nature of its sampling. A well-known and highly investigated biomarker for bladder cancer is survivin. For detection of very small amounts of urinary survivin protein a highly sensitive assay was developed. The assay is based on the immuno-PCR technology, more precisely a solid-phase proximity ligation assay (spPLA). The limit of detection for the survivin spPLA was 1.45 pg/mL, resulting in an improvement of the limit of detection by a factor of approximately 23 compared to the previously in-house developed survivin ELISA. A key step in development was the initial isolation of survivin by a molecular fishing rod based on magnetic beads. Interfering matrix compounds pose a special challenge for further analytical application, but can be overcome by this isolation step. The assay is designed to work with only 500 μL of voided urine. The survivin spPLA showed a sensitivity of 30% and specificity of 89% for bladder cancer detection in this study of 110 bladder cancer cases and 133 clinical controls. Moreover, the results demonstrated again that survivin is a useful complementary marker in combination with UBC® Rapid by increasing the overall sensitivity to 70% with a specificity of 86%. Although the performance for detection of bladder cancer was rather low, the herein developed assay might serve as a new tool for survivin biomarker research in diverse human fluids, even if the biological matrix is complex or survivin is only present in small amounts.
Identifiants
pubmed: 35767525
doi: 10.1371/journal.pone.0270535
pii: PONE-D-22-04954
pmc: PMC9242480
doi:
Substances chimiques
Biomarkers, Tumor
0
Inhibitor of Apoptosis Proteins
0
Survivin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0270535Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Urol. 2012 Aug 28;12:23
pubmed: 22928931
Anticancer Res. 2015 May;35(5):2651-5
pubmed: 25964541
Rev Urol. 2008 Spring;10(2):120-35
pubmed: 18660854
Cancer. 2007 Mar 15;109(6):1106-13
pubmed: 17311310
Talanta. 2021 Feb 1;223(Pt 1):121718
pubmed: 33303164
Chin J Cancer Res. 2013 Aug;25(4):375-81
pubmed: 23997523
Asian Pac J Cancer Prev. 2013;14(1):81-5
pubmed: 23534808
Anal Biochem. 2005 Oct 1;345(1):2-9
pubmed: 15950911
Expert Rev Proteomics. 2010 Jun;7(3):401-9
pubmed: 20536310
Nat Genet. 1999 Dec;23(4):387-8
pubmed: 10581018
IUBMB Life. 2010 May;62(5):394-9
pubmed: 20408180
Science. 1992 Oct 2;258(5079):120-2
pubmed: 1439758
Sci Rep. 2018 Sep 25;8(1):14321
pubmed: 30254313
Int J Mol Sci. 2020 Oct 08;21(19):
pubmed: 33050010
J Nippon Med Sch. 2004 Dec;71(6):379-83
pubmed: 15673958
Curr Opin Urol. 2019 May;29(3):203-209
pubmed: 30855372
Pharmaceutics. 2020 Oct 31;12(11):
pubmed: 33142793
Eur Urol Focus. 2018 Apr;4(3):388-394
pubmed: 28753799
Mol Cancer. 2017 Apr 14;16(1):80
pubmed: 28410618
Mol Cell Proteomics. 2010 Feb;9(2):327-35
pubmed: 19955079
Clin Chem. 2017 Jun;63(6):1061-1062
pubmed: 28249843
Biochemistry (Mosc). 2016 Dec;81(13):1754-1770
pubmed: 28260495
Nat Protoc. 2013 Jun;8(6):1234-48
pubmed: 23722261
J Cell Physiol. 2020 Feb;235(2):725-744
pubmed: 31250439
Pharmaceutics. 2020 Jul 09;12(7):
pubmed: 32659966
World J Urol. 2018 Sep;36(9):1373-1381
pubmed: 29610963
Mol Oncol. 2021 Jun;15(6):1715-1726
pubmed: 33012111
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
Cancer Lett. 2015 Sep 28;366(1):44-51
pubmed: 26118775
F1000Prime Rep. 2013 Jul 01;5:21
pubmed: 23864929
Anal Biochem. 2019 Dec 15;587:113444
pubmed: 31545948
Mol Cell Probes. 2016 Apr;30(2):106-12
pubmed: 26851193
Appl Environ Microbiol. 1997 Oct;63(10):3741-51
pubmed: 9327537
Urol Int. 2015;94(1):1-24
pubmed: 25501325
Nat Biotechnol. 2002 May;20(5):473-7
pubmed: 11981560
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
J Pers Med. 2021 Mar 23;11(3):
pubmed: 33806972
J Urol. 2002 Mar;167(3):1318-9; discussion 1319-20
pubmed: 11832722
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8420-4
pubmed: 15155907
Adv Anat Pathol. 2006 May;13(3):122-6
pubmed: 16778475
Stem Cell Rev Rep. 2020 Oct;16(5):828-852
pubmed: 32691369
Nat Rev Urol. 2021 Apr;18(4):185-187
pubmed: 33335321
BJUI Compass. 2020 Oct 20;2(1):46-52
pubmed: 35474659
J Exp Med. 2004 May 17;199(10):1343-54
pubmed: 15148334
Biomed Res Int. 2015;2015:681416
pubmed: 26819954
Angew Chem Int Ed Engl. 2021 Feb 1;60(5):2221-2231
pubmed: 32282107
Urol Oncol. 2020 Dec;38(12):886-895
pubmed: 32199755
Biochim Biophys Acta. 2014 May;1844(5):874-83
pubmed: 24361552
Diagnostics (Basel). 2020 Jan 13;10(1):
pubmed: 31941070
Anal Chim Acta. 2016 Mar 3;910:12-24
pubmed: 26873464
PLoS One. 2013 Oct 18;8(10):e76719
pubmed: 24204662
Biochim Biophys Acta. 2014 Jan;1844(1 Pt A):145-55
pubmed: 23939561
Oncol Rep. 2018 Jun;39(6):2817-2828
pubmed: 29658613
J Cell Sci. 2019 Apr 4;132(7):
pubmed: 30948431
Int Arch Occup Environ Health. 2014;87(7):715-24
pubmed: 24129706
Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv
pubmed: 20082749
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
J Appl Microbiol. 2012 Nov;113(5):1014-26
pubmed: 22747964
Int J Mol Sci. 2018 Jan 11;19(1):
pubmed: 29324722